featured
Valemetostat Monotherapy for Relapsed or Refractory Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study
Lancet Oncol 2024 Oct 29;[EPub Ahead of Print], D Maruyama, E Jacobsen, P Porcu, P Allen, K Ishitsuka, S Kusumoto, T Narita, K Tobinai, F Foss, K Tsukasaki, T Feldman, Y Imaizumi, K Izutsu, S Morishima, N Yamauchi, J Yuda, JE Brammer, T Kawamata, J Ruan, K Nosaka, A Utsunomiya, J Wang, J Zain, Y Kakurai, H Yamauchi, Y Hizukuri, N Biserna, M Tachibana, A Inoue, SM HorwitzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.